In focus · trending topic

Early Access Program

2 stories · following the connections

Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer

By Nasdaq OMXJul 10, 2017, 12:30 PM UTC

Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe

By Nasdaq OMXJan 26, 2017, 3:51 PM UTC